Geode Capital Management LLC Acquires 127,708 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Geode Capital Management LLC lifted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 2.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 4,837,985 shares of the biotechnology company’s stock after buying an additional 127,708 shares during the period. Geode Capital Management LLC’s holdings in BioCryst Pharmaceuticals were worth $36,776,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of BCRX. Counterweight Ventures LLC boosted its position in shares of BioCryst Pharmaceuticals by 591.7% during the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock worth $710,000 after acquiring an additional 79,884 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in BioCryst Pharmaceuticals by 40.7% during the third quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock worth $2,274,000 after purchasing an additional 86,571 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of BioCryst Pharmaceuticals by 299.0% in the 2nd quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company’s stock valued at $970,000 after purchasing an additional 117,607 shares in the last quarter. Seven Eight Capital LP lifted its position in shares of BioCryst Pharmaceuticals by 1,407.1% during the 2nd quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock worth $1,048,000 after buying an additional 158,358 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its stake in shares of BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after purchasing an additional 84,102 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

Analyst Ratings Changes

BCRX has been the subject of several research reports. Barclays increased their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $15.60.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $7.67 on Wednesday. The company has a market capitalization of $1.59 billion, a P/E ratio of -12.57 and a beta of 1.79. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88. The business has a fifty day simple moving average of $7.63 and a two-hundred day simple moving average of $7.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. The company’s quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.19) earnings per share. As a group, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.